SecBot SecBot
Insider Cluster (6 insiders) ·Filed May 15, 2026

KPTI

Karyopharm Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago
Insider cluster: 6 insiders, $0.0M total
Actionable Insight • Neutral

The insider sales are too small to be informative. Focus on the $400M shelf registration and going-concern risk: KPTI must raise capital by late Q3 2026, which will likely cause severe dilution. Monitor for any ATM debuts or equity offering announcements.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.14
T+0 close · May 15, 2026 · via day close
Latest settled
−71.57%
T+60 · $2.03
Vs SPY
−76.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $7.14entry
  2. T+1 · 6mo ago +4.62%α +5.27% · $7.47
  3. T+5 · 6mo ago +25.63%α +24.01% · $8.97
  4. T+20 · 5mo ago +27.45%α +25.87% · $9.10
  5. T+60 · 3mo ago −71.57%α −76.42% · $2.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Six KPTI insiders, including the CEO and other C-suite executives, sold a total of $35K in shares on May 14, 2026, the same day as the Q1 earnings release. The sales are minimal in size (0.019% of market cap) and likely routine post-earnings transactions. Three directors received non-cash stock grants on May 21. The sales do not signal bearish sentiment given their trivial value, but the company faces significant going-concern risk and potential dilution from a $400M shelf registration.

Key Financial Metrics

Direction
selling
Total Value
$35.0K
Insiders
6

Key Facts

  • Six C-suite insiders sold a total of $35K in shares on May 14, 2026, all at $9.50/share.
  • Three directors received grants of 15,508 shares each on May 21, 2026, at $0 (non-cash).
  • Total insider sales represent 0.019% of KPTI's $185M market cap, well below materiality threshold.
  • Q1 2026 revenue was $35.1M (up 17% YoY), net loss $22.4M, beat consensus EPS of -$1.44 by 29%.
  • Phase 3 SENTRY myelofibrosis trial missed second co-primary endpoint; $400M shelf registration filed.
  • Cash runway extends only into late Q3 2026, creating acute financing risk.

Financial Impact

Insider sales of $35K are immaterial; the shelf registration of $400M (216% of market cap) is the key risk.

dilutioncash runway

Risk Factors

  • Potential massive dilution from the $400M shelf registration relative to $185M market cap.
  • Going concern with cash runway only to late Q3 2026.
  • Phase 3 SENTRY trial failure limits pipeline upside.
  • Insider sales, while small, occur amid high uncertainty.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KPTI-1779826471396

US Market Status

Market Closed · Opens in 8h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026